EWA
BCAX

EverSource Wealth Advisors’s Bicara Therapeutics BCAX Stock Holding History

EverSource Wealth Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.27K Buy
315
+6
+2% +$103 ﹤0.01% 3160
2025
Q4 		$5.2K Sell
309
-60
-16% -$1.02K ﹤0.01% 3105
2025
Q3 		$5.83K Buy
369
+291
+373% +$3.26K ﹤0.01% 3091
2025
Q2 		$724 Sell
78
-24
-24% -$286 ﹤0.01% 3808
2025
Q1 		$1.33K Buy
+102
New +$1.35K ﹤0.01% 3109

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

EverSource Wealth Advisors's BCAX Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Bicara Therapeutics (BCAX) stake by 1.9% in Q1 2026, buying an estimated $103 and bringing the position to 315 shares worth $6.27K. The position accounts for ﹤0.01% of the portfolio, ranked #3160.

EverSource Wealth Advisors first reported a position in BCAX in Q1 2025 and has held it in 5 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • EverSource Wealth Advisors held 315 shares of Bicara Therapeutics worth $6.27K as of Q1 2026.
  • EverSource Wealth Advisors bought 6 Bicara Therapeutics shares in Q1 2026, an estimated $103.
  • Bicara Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3160 holding.
  • EverSource Wealth Advisors first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.